Search

Your search keyword '"Gong, Youling"' showing total 292 results
Start Over Author "Gong, Youling"
292 results on '"Gong, Youling"'

5. Survival of Patients With Inoperable Non--Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation Pneumonitis

Author

Deng, Qianyue, Zhang, Yingjie, Li, Yanying, Mei, Ting, Yang, Xuexi, Tian, Xiaoman, Chen, Xianyan, and Gong, Youling

Subjects
Oncology, Experimental -- Analysis, Bacterial pneumonia -- Care and treatment -- Patient outcomes, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Radiation -- Analysis, Pemetrexed -- Analysis, Pneumonia -- Care and treatment -- Patient outcomes, Chemotherapy -- Analysis, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Cancer -- Chemotherapy -- Research, Radiotherapy -- Analysis, Health
Abstract

BACKGROUND AND PURPOSE. Currently, there is no standard treatment for patients with lung cancer with deteriorated pulmonary function. In this study, we aimed to assess the efficacy of thoracic radiotherapy for unresectable non-small cell lung cancer (NSCLC) with baseline severe pulmonary dysfunction and severe acute radiation pneumonitis (SARP). METHODS. Patients were categorized into a radiotherapy group and a nonradiotherapy group, followed by analysis of clinical variables. A Cox regression was used to evaluate the impact of various factors on overall survival (OS). Each SARP factor's predictive value was assessed using logistic regression, receiver operating characteristic curve, and Kaplan-Meier analyses. RESULTS. The median OS in the radiotherapy group was 21.6 months vs 8.9 months in the nonradiotherapy group. Cox analysis revealed that chemotherapy (HR, 0.221; 95% CI, 0.149-0.329; P < .0013 and radiotherapy (HR, 0.589; 95% CI, 0.399-0.869; P = .008) are independent prognostic factors for the current cohort. The data suggested that the ipsilateral lung V10 (iIV10, the percentage of the lung volume that received more than 10 Gy) was an independent predictor of SARP. CONCLUSIONS. Our findings suggested that thoracic radiotherapy might be associated with clinical benefits to inoperable NSCLC in patients with severe pulmonary dysfunction and that ilV10 may be involved in the prediction of risk for SARP in these patients. KEYWORDS. Severe pulmonary dysfunction; non-small cell lung cancer; thoracic radiotherapy; predictive factors; severe acute radiation pneumonitis, Introduction Smokers with chronic obstructive pulmonary disease (COPD) have a 2 to 5 times higher lung cancer risk than non-COPD smokers. (1-4) According to international guidelines, a ratio of forced [...]

Published
2023

6. KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming

Author

Na, Feifei, Pan, Xiangyu, Chen, Jingyao, Chen, Xuelan, Wang, Manli, Chi, Pengliang, You, Liting, Zhang, Lanxin, Zhong, Ailing, Zhao, Lei, Dai, Siqi, Zhang, Mengsha, Wang, Yiyun, Wang, Bo, Zheng, Jianan, Wang, Yuying, Xu, Jing, Wang, Jian, Wu, Baohong, Chen, Mei, Liu, Hongyu, Xue, Jianxin, Huang, Meijuan, Gong, Youling, Zhu, Jiang, Zhou, Lin, Zhang, Yan, Yu, Min, Tian, Panwen, Fan, Mingyu, Lu, Zhenghao, Xue, Zhihong, Zhao, Yinglan, Yang, Hanshuo, Zhao, Chengjian, Wang, Yuan, Han, Junhong, Yang, Shengyong, Xie, Dan, Chen, Lu, Zhong, Qian, Zeng, Musheng, Lowe, Scott W., Lu, You, Liu, Yu, Wei, Yuquan, and Chen, Chong

Published
2022
Full Text
View/download PDF

8. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis

Author

Tian, Tian, primary, Li, Yanying, additional, Li, Juan, additional, Xu, Hongyu, additional, Fan, Hua, additional, Zhu, Jiang, additional, Wang, Yongsheng, additional, Peng, Feng, additional, Gong, Youling, additional, Du, Yijia, additional, Yan, Xiaoyan, additional, He, Xiulan, additional, Daylan, Ayse Ece Cali, additional, Pircher, Andreas, additional, Neibart, Shane S., additional, Okuma, Yusuke, additional, Hong, Min Hee, additional, Huang, Meijuan, additional, and Lu, You, additional

Published
2024
Full Text
View/download PDF

10. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Cheng, Ying, Wang, Jie, Zhou, Caicun, Yao, Wenxiu, Wang, Qiming, Min, Xuhong, Chen, Gongyan, Xu, Xingxiang, Li, Xingya, Xu, Fei, Fang, Yong, Yang, Runxiang, Yu, Guohua, Gong, Youling, Zhao, Jun, Fan, Yun, Liu, Quan, Cao, Lejie, Yao, Yu, Liu, Yunpeng, Li, Xiaoling, Wu, Jingxun, He, Zhiyong, Lu, Kaihua, Jiang, Liyan, Hu, Chengping, Zhao, Wenhua, Yu, Huiqing, Zhao, Jian, Wu, Gang, Huang, Dingzhi, Chen, Chengshui, Ding, Cuimin, Zhang, Baihong, Wang, Xiuwen, Luo, Hui, Li, Baolan, Zhang, Shucai, Lu, Hong, Shi, Meiqi, Chen, Xi, Guo, Yubiao, Liu, Hailong, Liu, Jiwei, Gao, Hongjun, Hu, Sheng, Hong, Qunying, Li, Qi, Zhang, Ben, Shi, Wei, and Zhang, Xiaojing

Published
2022
Full Text
View/download PDF

12. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Author

Zhou, Qing, Chen, Ming, Jiang, Ou, Pan, Yi, Hu, Desheng, Lin, Qin, Wu, Gang, Cui, Jiuwei, Chang, Jianhua, Cheng, Yufeng, Huang, Cheng, Liu, Anwen, Yang, Nong, Gong, Youling, Zhu, Chuan, Ma, Zhiyong, Fang, Jian, Chen, Gongyan, Zhao, Jun, Shi, Anhui, Lin, Yingcheng, Li, Guanghui, Liu, Yunpeng, Wang, Dong, Wu, Rong, Xu, Xinhua, Shi, Jianhua, Liu, Zhihua, Cui, Na, Wang, Jingru, Wang, Qiang, Zhang, Ran, Yang, Jason, and Wu, Yi-Long

Published
2022
Full Text
View/download PDF

14. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

Author

Zheng, Jing, primary, Wang, Tao, additional, Yang, Yunpeng, additional, Huang, Jie, additional, Feng, Jifeng, additional, Zhuang, Wu, additional, Chen, Jianhua, additional, Zhao, Jun, additional, Zhong, Wei, additional, Zhao, Yanqiu, additional, Zhang, Yiping, additional, Song, Yong, additional, Hu, Yi, additional, Yu, Zhuang, additional, Gong, Youling, additional, Chen, Yuan, additional, Ye, Feng, additional, Zhang, Shucai, additional, Cao, Lejie, additional, Fan, Yun, additional, Wu, Gang, additional, Guo, Yubiao, additional, Zhou, Chengzhi, additional, Ma, Kewei, additional, Fang, Jian, additional, Feng, Weineng, additional, Liu, Yunpeng, additional, Zheng, Zhendong, additional, Li, Gaofeng, additional, Wang, Huijie, additional, Cang, Shundong, additional, Wu, Ning, additional, Song, Wei, additional, Liu, Xiaoqing, additional, Zhao, Shijun, additional, Ding, Lieming, additional, Selvaggi, Giovanni, additional, Wang, Yang, additional, Xiao, Shanshan, additional, Wang, Qian, additional, Shen, Zhilin, additional, Zhou, Jianya, additional, Zhou, Jianying, additional, and Zhang, Li, additional

Published
2024
Full Text
View/download PDF

16. Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing

Author

Yang, Yunpeng, Huang, Jie, Wang, Tao, Zhou, Jianya, Zheng, Jing, Feng, Jifeng, Zhuang, Wu, Chen, Jianhua, Zhao, Jun, Zhong, Wei, Zhao, Yanqiu, Zhang, Yiping, Song, Yong, Hu, Yi, Yu, Zhuang, Gong, Youling, Chen, Yuan, Ye, Feng, Zhang, Shucai, Cao, Lejie, Fan, Yun, Wu, Gang, Guo, Yubiao, Zhou, Chengzhi, Ma, Kewei, Fang, Jian, Feng, Weineng, Liu, Yunpeng, Zheng, Zhendong, Li, Gaofeng, Wang, Huijie, Cang, Shundong, Wu, Ning, Song, Wei, Liu, Xiaoqing, Zhao, Shijun, Ding, Lieming, Mao, Li, Selvaggi, Giovanni, Zhu, Larry, Xiao, Shanshan, Yuan, Xiaobin, Shen, Zhilin, and Zhang, Li

Published
2021
Full Text
View/download PDF

17. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer

Author

Yin, Limei, Xue, Jianxin, Li, Rui, Zhou, Lin, Deng, Lei, Chen, Lin, Zhang, Yan, Li, Yanying, Zhang, Xuanwei, Xiu, Weigang, Tong, Ruizhan, Gong, Youling, Huang, Meijuan, Xu, Yong, Zhu, Jiang, Yu, Min, Li, Mengqian, Lan, Jie, Wang, Jin, Mo, Xianming, Wei, Yuquan, Niedermann, Gabriele, and Lu, You

Published
2020
Full Text
View/download PDF

19. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Author

Yang, Yunpeng, Zhou, Jianya, Zhou, Jianying, Feng, Jifeng, Zhuang, Wu, Chen, Jianhua, Zhao, Jun, Zhong, Wei, Zhao, Yanqiu, Zhang, Yiping, Song, Yong, Hu, Yi, Yu, Zhuang, Gong, Youling, Chen, Yuan, Ye, Feng, Zhang, Shucai, Cao, Lejie, Fan, Yun, Wu, Gang, Guo, Yubiao, Zhou, Chengzhi, Ma, Kewei, Fang, Jian, Feng, Weineng, Liu, Yunpeng, Zheng, Zhendong, Li, Gaofeng, Wu, Ning, Song, Wei, Liu, Xiaoqing, Zhao, Shijun, Ding, Lieming, Mao, Li, Selvaggi, Giovanni, Yuan, Xiaobin, Fu, Yuanqing, Wang, Tao, Xiao, Shanshan, and Zhang, Li

Published
2020
Full Text
View/download PDF

21. Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients

Author

Zhou, Xiaojuan, primary, Zhou, Laiyan, primary, Yao, Zhuoran, primary, Huang, Meijuan, primary, Gong, Youling, primary, Zou, Bingwen, primary, Zhu, Jiang, primary, Liu, Yongmei, primary, Peng, Feng, primary, Zhang, Yan, primary, Yu, Min, primary, Li, Yanying, primary, Na, Feifei, primary, Wu, Yijun, primary, Kang, Kai, primary, Xiu, Weigang, primary, Zhang, Xuanwei, primary, Zhou, Lin, primary, Xu, Yong, primary, Wang, Jin, primary, Wang, Yan, primary, Yang, Xue, primary, Wu, Yuanjun, primary, Li, Rui, primary, Zhang, Yu, primary, Yang, Zhenzhou, primary, Zhou, Zhipeng, primary, Bai, Jing, primary, Yi, Xin, primary, Tong, Ruizhan, primary, Yin, Limei, primary, Chen, Chong, primary, Niedermann, Gabriele, primary, Lu, You, primary, and Xue, Jianxin, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients

Author

Zhou, Xiaojuan, primary, Zhou, Laiyan, primary, Yao, Zhuoran, primary, Huang, Meijuan, primary, Gong, Youling, primary, Zou, Bingwen, primary, Zhu, Jiang, primary, Liu, Yongmei, primary, Peng, Feng, primary, Zhang, Yan, primary, Yu, Min, primary, Li, Yanying, primary, Na, Feifei, primary, Wu, Yijun, primary, Kang, Kai, primary, Xiu, Weigang, primary, Zhang, Xuanwei, primary, Zhou, Lin, primary, Xu, Yong, primary, Wang, Jin, primary, Wang, Yan, primary, Yang, Xue, primary, Wu, Yuanjun, primary, Li, Rui, primary, Zhang, Yu, primary, Yang, Zhenzhou, primary, Zhou, Zhipeng, primary, Bai, Jing, primary, Yi, Xin, primary, Tong, Ruizhan, primary, Yin, Limei, primary, Chen, Chong, primary, Niedermann, Gabriele, primary, Lu, You, primary, and Xue, Jianxin, primary

Published
2023
Full Text
View/download PDF

23. Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival

Author

Chen, Xianyan, primary, Zhang, Yingjie, additional, Zhou, Xiaojuan, additional, Wang, Min, additional, Na, Feifei, additional, Zhou, Lin, additional, Xu, Yong, additional, Zou, Bingwen, additional, Xue, Jianxin, additional, Liu, Yongmei, additional, and Gong, Youling, additional

Published
2023
Full Text
View/download PDF

24. First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab？

Author

Zhao, Yuanyuan, primary, Mei, Ting, additional, Na, Feifei, additional, Tian, Xiaoman, additional, Ao, Rui, additional, Long, Xiangyu, additional, Luo, Qiang, additional, Duan, Ping, additional, Zhu, Jiang, additional, Wang, Yongsheng, additional, Huang, Meijuan, additional, Liu, Yongmei, additional, and Gong, Youling, additional

Published
2023
Full Text
View/download PDF

28. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Author

Lu, You, Xue, Jianxin, Deng, Tao, Zhou, Xiaojuan, Yu, Kun, Deng, Lei, Huang, Meijuan, Yi, Xin, Liang, Maozhi, Wang, Yu, Shen, Haige, Tong, Ruizhan, Wang, Wenbo, Li, Li, Song, Jin, Li, Jing, Su, Xiaoxing, Ding, Zhenyu, Gong, Youling, Zhu, Jiang, Wang, Yongsheng, Zou, Bingwen, Zhang, Yan, Li, Yanying, Zhou, Lin, Liu, Yongmei, Yu, Min, Wang, Yuqi, Zhang, Xuanwei, Yin, Limei, Xia, Xuefeng, Zeng, Yong, Zhou, Qiao, Ying, Binwu, Chen, Chong, Wei, Yuquan, Li, Weimin, and Mok, Tony

Published
2020
Full Text
View/download PDF

31. Optimal timing of hypofractionated stereotactic radiotherapy for epidermal growth factor receptor‐mutated non‐small‐cell lung cancer patients with brain metastases.

Author

Liang, Shimeng, Liu, Xiaoqin, Liu, Jia, Na, Feifei, Lai, Jialu, Du, Leiya, Gong, Youling, Zhu, Jiang, Huang, Meijuan, Zhou, Xiaojuan, Xu, Yong, and Zhou, Lin

Subjects
NON-small-cell lung carcinoma, EPIDERMAL growth factor, STEREOTACTIC radiotherapy, EPIDERMAL growth factor receptors, CANCER patients
Abstract

Background: For epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer (NSCLC) patients with limited brain metastases (BMs), who eventually receive both tyrosine kinase inhibitors (TKIs) treatment and brain radiotherapy, the optimal timing of radiotherapy is not clear. The present retrospective analysis aimed to partly solve this problem. Methods: In total 84 EGFR‐mutated NSCLC patients with limited BMs, who received both TKI treatment and brain hypofractionated stereotactic radiotherapy (HSRT), were enrolled. Patients were divided into three groups based on whether the HSRT was administrated 2 weeks before or after the beginning of TKI treatment (upfront HSRT), when intracranial lesions stabilized after TKI treatment (consolidative HSRT), or when the intracranial disease progressed after TKI treatment (salvage HSRT). The clinical efficacy and toxicities were evaluated. Results: The median intracranial progression‐free survival (iPFS) and overall PFS calculated from the initiation of HSRT (iPFS1 and PFS1) of all patients were 17.5 and 13.1 months, respectively. The median iPFS and PFS calculated from the initiation of TKI treatment (iPFS2 and PFS2) of all patients were 24.1 and 18.4 months, respectively. Compared to consolidative and salvage HSRT, upfront HSRT improved iPFS1 (not reached vs. 17.5 months vs. 11.0 months, p < 0.001) and PFS1 (18.4 months vs. 9.1 months vs. 7.9 months, p < 0.001), and reduced the initial intracranial failure rate (12.5% vs. 48.1% vs. 56%, p < 0.001). However, there were no significant differences between the three groups for iPFS2, PFS2, and overall survival. Hepatic metastases and diagnosis‐specific Graded Prognostic Assessment (ds‐GPA) at 2–3 were poor prognostic factors. Conclusion: For patients who receive both TKI treatment and brain HSRT, the timing of HSRT does not seem to influence the eventual therapeutic effect. Further validation in prospective clinical studies is needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients

Author

Zhou, Xiaojuan, primary, Zhou, Laiyan, additional, Yao, Zhuoran, additional, Huang, Meijuan, additional, Gong, Youling, additional, Zou, Bingwen, additional, Zhu, Jiang, additional, Liu, Yongmei, additional, Peng, Feng, additional, Zhang, Yan, additional, Yu, Min, additional, Li, Yanying, additional, Na, Feifei, additional, Wu, Yijun, additional, Kang, Kai, additional, Xiu, Weigang, additional, Zhang, Xuanwei, additional, Zhou, Lin, additional, Xu, Yong, additional, Wang, Jin, additional, Wang, Yan, additional, Yang, Xue, additional, Wu, Yuanjun, additional, Li, Rui, additional, Zhang, Yu, additional, Yang, Zhenzhou, additional, Zhou, Zhipeng, additional, Bai, Jing, additional, Yi, Xin, additional, Tong, Ruizhan, additional, Yin, Limei, additional, Chen, Chong, additional, Niedermann, Gabriele, additional, Lu, You, additional, and Xue, Jianxin, additional

Published
2023
Full Text
View/download PDF

33. Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy

Author

Chen, Xianyan, primary, Tian, Xiaoman, additional, Zhang, Xuanwei, additional, Deng, Qianyue, additional, Wang, Min, additional, Zhou, Xiaojuan, additional, Xu, Yong, additional, Zhou, Lin, additional, Zou, Bingwen, additional, Liu, Yongmei, additional, Ao, Rui, additional, Lu, You, additional, and Gong, Youling, additional

Published
2023
Full Text
View/download PDF

34. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.

Author

Zhang, Yan, primary, Zhou, Lin, additional, Gong, Youling, additional, Huang, Meijuan, additional, Tang, Min, additional, Liu, Yongmei, additional, Yu, Min, additional, Xiu, Weigang, additional, Liang, Xinjun, additional, Liu, Xinyu, additional, Fu, Xin-Yuan, additional, and Lu, You, additional

Published
2023
Full Text
View/download PDF

37. Abstract CT219: Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study

Author

Zhou, Lin, primary, Sun, Jianguo, additional, Xie, Conghua, additional, Gong, Youling, additional, Huang, Meijuan, additional, Yuan, Zhiyong, additional, Wu, Lin, additional, Wang, Hui, additional, Bi, Nan, additional, Xu, Yaping, additional, Zhu, Jiang, additional, Liu, Yongmei, additional, Zhang, Yan, additional, Fan, Min, additional, Zou, Bingwen, additional, Yu, Min, additional, Li, Yanying, additional, Na, Feifei, additional, Xiu, Weigang, additional, Xu, Yong, additional, Wang, Jin, additional, Zhang, Xuanwei, additional, Xue, Jianxin, additional, and Lu, You, additional

Published
2023
Full Text
View/download PDF

40. Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study

Author

Qin, Yi, primary, Long, Yaling, additional, Tang, Yuan, additional, Tian, Yuke, additional, Li, Juan, additional, Duan, Ping, additional, Luo, Jieyan, additional, Yu, Min, additional, Li, Yanying, additional, Zhou, Xiaojuan, additional, Wang, Ke, additional, Gong, Youling, additional, Peng, Feng, additional, Zhu, Jiang, additional, Liu, Yongmei, additional, Zhou, Lin, additional, Lu, You, additional, and Huang, Meijuan, additional

Published
2023
Full Text
View/download PDF

47. Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Author

Lu, You, Xue, Jianxin, Deng, Tao, Zhou, Xiaojuan, Yu, Kun, Deng, Lei, Huang, Meijuan, Yi, Xin, Liang, Maozhi, Wang, Yu, Shen, Haige, Tong, Ruizhan, Wang, Wenbo, Li, Li, Song, Jin, Li, Jing, Su, Xiaoxing, Ding, Zhenyu, Gong, Youling, Zhu, Jiang, Wang, Yongsheng, Zou, Bingwen, Zhang, Yan, Li, Yanying, Zhou, Lin, Liu, Yongmei, Yu, Min, Wang, Yuqi, Zhang, Xuanwei, Yin, Limei, Xia, Xuefeng, Zeng, Yong, Zhou, Qiao, Ying, Binwu, Chen, Chong, Wei, Yuquan, Li, Weimin, and Mok, Tony

Published
2020
Full Text
View/download PDF

48. Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial

Author

Cheng, Ying, primary, Wang, Jie, additional, Zhou, Caicun, additional, Yao, Wenxiu, additional, Wang, Qiming, additional, Min, Xuhong, additional, Chen, Gongyan, additional, Xu, Xingxiang, additional, Li, Xingya, additional, Xu, Fei, additional, Fang, Yong, additional, Yang, Runxiang, additional, Yu, Guohua, additional, Gong, Youling, additional, Zhao, Jun, additional, Fan, Yun, additional, Liu, Quan, additional, Cao, Lejie, additional, Yao, Yu, additional, Liu, Yunpeng, additional, Li, Xiaoling, additional, Wu, Jingxun, additional, He, Zhiyong, additional, Lu, Kaihua, additional, Jiang, Liyan, additional, Yu, Huiqing, additional, Hu, Chengping, additional, Zhao, Wenhua, additional, Zhao, Jian, additional, Wu, Gang, additional, Huang, Dingzhi, additional, Chen, Chengshui, additional, Ding, Cuimin, additional, Zhang, Baihong, additional, Wang, Xiuwen, additional, Luo, Hui, additional, Li, Baolan, additional, Zhang, Ben, additional, Li, Haowen, additional, and Ma, Ke, additional

Published
2022
Full Text
View/download PDF

49. Abstract CT510: A phase I clinical trial of 3D-pluripotent stem cell biologics in heavily treated advanced NSCLC patients

Author

Huang, Meijuan, primary, Chen, Xiancheng, additional, Qin, Yi, additional, Long, Yaling, additional, Li, Qian, additional, Zhang, Yanna, additional, Yu, Min, additional, Hou, Panyan, additional, Liu, Nanxi, additional, Li, Yanying, additional, Yu, Yang, additional, Zhou, Xiaojuan, additional, Gong, Youling, additional, Wang, Ke, additional, Zhu, Jiang, additional, Peng, Feng, additional, Wang, Yongsheng, additional, Lu, You, additional, and Wei, Yuquan, additional

Published
2022
Full Text
View/download PDF

50. Abstract 5569: CAR-T cells with αPDL1/CD28 switch-receptor synergize radiotherapy and anti-PD1 therapy in solid tumors

Author

Yin, Limei, primary, Wang, Wenbo, additional, Yao, Zhuoran, additional, Xue, Jianxin, additional, Tong, Ruizhan, additional, Wang, Hui, additional, Liao, Shuangsi, additional, Wang, Laduona, additional, Zheng, Yue, additional, Na, Feifei, additional, Yu, Min, additional, Zhang, Xuanwei, additional, Gong, Youling, additional, Huang, Meijuan, additional, Mo, Xianming, additional, Chen, Chong, additional, and Lu, You, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results